{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Bowel movements without flushing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Bowel movements with flushing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"No Bowel movement or Flushing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Number of bowel movements and flushing during period 0 and 1, data is presented as patients experience symptoms\n\nBowel movement without flushing Bowel movement and flushing No Bowel movement or Flushing","groups":[{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks\n\noctreotide FluidCrystal® injection depot","id":"OG000","title":"CAM2029 10 mg q2w (NET)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly\n\noctreotide FluidCrystal® injection depot","id":"OG001","title":"CAM2029 20 mg q4w (NET)"}],"paramType":"NUMBER","populationDescription":"Pharmacokinetic population","reportingStatus":"POSTED","timeFrame":"Baseline (Day 0), Day 84","title":"To Assess the Symptoms of Carcinoid Syndrome (Number of Bowel Movements and Flushing) and the Use of Rescue Medication Versus Baseline (by Using Patient Diaries) (NET)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"participants"}